Medicalsystem Biotechnology released its 2026 interim report. The company's total operating revenue was 828 million yuan, and net profit attributable to the parent company was 61.9492 million yuan. Net cash inflow from operating activities was 62.581 million yuan, down 35.01% from the same period last year. The company's latest asset-liability ratio was 19.19%, gross margin was 35.47%, ROE was 2.06%, and diluted earnings per share was 0.16 yuan. The number of shareholders was 21,200, and the top ten shareholders held 49.24% of the total share capital.
Ningbo MedicalSystem Biotechnology Co LtdInterim report shows net profit of 61.9M yuan on revenue of 828M, but cash flow from operations fell 35.01%.
